The Role of Tumor Suppressor WWOX in Modulating PD-L1 Expression in Breast Cancers

Abstract

Objective: This study aimed to determine the potential contribution of WWOX to the regulation of PD-L1 expression in breast cancer. Materials and Methods: MDA-MB-231, MCF-7, and MCF10A cell lines were used in this study. The WWOX gene was overexpressed in MDA-MB-231 cells using the pCMV-WWOX expression vector. In MCF-7 and MCF10A cells, WWOX expression was silenced using siRNA specifically targeting the WWOX gene. WWOX and PD-L1 mRNA expression in each cell group was analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR), with GAPDH used as the endogenous normalization control. The presence and relative levels of WWOX, PD-L1, and GAPDH proteins were examined by Western blotting. Results: In MDA-MB-231, overexpression of WWOX led to a statistically significant decrease in PD-L1 mRNA levels (p=0.037). In MCF-7 and the non-tumorigenic epithelial cell line MCF10A, transient knockdown of WWOX significantly increased PD-L1 mRNA expression in MCF10A cells (p=0.043), whereas the increase in MCF-7 cells did not show statistical significance (p>0.05). Consistent with the RT-qPCR findings, MDA-MB-231 cells transfected with the pCMVWWOX vector showed increased WWOX protein levels and a concomitant decrease in PD-L1 protein levels. Conclusion: Our findings suggest that the loss of WWOX may enhance tumor immune escape mechanisms via PDL1, particularly in triple-negative breast cancer (TNBC) cells. Clarification of the WWOX/PD-L1 relationship at the molecular and translational levels will require expanded research.

Keywords

• Immune escape
• PD-L1
• WWOX
• Breast cancer

References

1. 1. Baryła I, Styczeń-Binkowska E, Bednarek AK. Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) 2015; 240(3): 305-14. google scholar
2. 2. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews, JM, et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463(7283), 893–8. google scholar
3. 3. Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH, et al. WWOX-Brca1 interaction: role in DNA repair pathway choice. Oncogene 2017; 36(16): 2215–27. google scholar
4. 4. Abu-Remaileh M, Joy-Dodson E, Schueler-Furman O, Aqeilan RI. Pleiotropic functions of tumor suppressor WWOX in normal and cancer cells. J Biol Chem 2015; 290(52): 30728–35. google scholar
5. 5. Aldaz CM, Ferguson BW, Abba MC. WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta 2014; 1846(1): 188– 200. google scholar
6. 6. Pospiech K, Płuciennik E, Bednarek AK. WWOX tumor suppressor gene in breast cancer, a historical perspective and future directions. Front Oncol 2018; 8: 345. google scholar
7. 7. Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018; 31(2): 214–34. google scholar
8. 8. Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis 2020; 11(11): 955. google scholar

9. 9. Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016; 21(3): 462–73. google scholar
10. 10. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PDL1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15(3): 971–9. google scholar
11. 11. Karasar P, Esendağlı G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat 2014; 145(3): 605–14. google scholar
12. 12. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125(9): 3384–91. google scholar
13. 13. Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother 2021; 70(3): 607–17. google scholar
14. 14. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, et al. EBV-driven LMP1 and IFN-γ upregulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 2014; 5(23): 12189–202. google scholar
15. 15. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 2015; 51(3): 221–8. google scholar
16. 16. Chang R, Song L, Xu Y, Wu Y, Dai C, Wang X, et al. Loss of WWOX drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis. Nat Commun 2018; 9(1): 3486. google scholar
17. 17. Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, et al. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer. Clin Breast Cancer 2018; 18(5): e1205–e1215. google scholar
18. 18. Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple-negative breast cancer: a systematic review. J Exp Clin Cancer Res 2019; 38(1): 195. google scholar
19. 19. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 2017; 19(6): 1189–1201. google scholar
20. 20. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: a matter of balance. JAK-STAT 2012; 1(2): 65-72. google scholar